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Combined large cell neuroendocrine carcinoma of the lungs (combined LCNEC) with giant cell carcinoma is
extremely rare. A 65-year-old man was found to have an abnormal shadow in his left lung field. Computed
tomography revealed a solid, round mass measuring 2.8 × 2.2 cm that was located in the left S9. The patient
underwent left lower lobectomy and mediastinal lymph node dissection. Histopathological examination revealed an
LCNEC, combined with giant cell carcinoma. The patient received by S-1 (TS-1, an oral fluoropyrimidine)
chemotherapy, and he has been disease-free for over 8 months. Combined LCNEC with giant cell carcinoma is an
extremely rare tumor with high malignant potential, and thus, multidisciplinary therapy and close follow-up are
advised.
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Combined large cell neuroendocrine carcinoma (com-
bined LCNEC) is a rare histological type of primary lung
carcinoma that has components of adenocarcinoma, squa-
mous cell carcinoma, giant cell carcinoma, and/or spindle
cell carcinoma. In 1999, the World Health Organization
(WHO) categorized combined LCNEC as a variant of
large cell carcinoma (LCC). Combined LCNEC accounts
for only 10.6% of all LCNECs. In this context, we report a
case of combined LCNEC with giant cell carcinoma that
we encountered recently.Case presentation
A 65-year-old man was found to have an abnormal
shadow in his left lung field. A mass was detected in the
left middle lung field on a chest radiograph (Figure 1A).
Computed tomography (CT) revealed a solid, round mass
measuring 2.8 × 2.2 cm located in the left S9 (Figure 1B).
No mediastinal lymph node swelling or other organ me-
tastases were observed. On positron emission tomography
with 18F-fluorodeoxyglucose examination, the maximum* Correspondence: shayashi@asahikawa-med.ac.jp
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reproduction in any medium, provided the orstandardized uptake value was 12.1, which corresponded to
the tumor findings on CT (Figure 1C). Biochemical blood
examinations did not reveal abnormalities, and the levels of
the tumor markers carcinoembryonic antigen (CEA), squa-
mous cell carcinoma antigen, Cyfra21-1/cytokeratin 19
fragment, and pro-gastrin-releasing peptide were 3.0 ng/ml,
1.9 ng/ml, 2.1 ng/ml, and 30.9 pg/ml, respectively. The pa-
tient had received radiation therapy (66 Gy/33 fr) and
chemotherapy (super selective intra-arterial chemotherapy,
cisplatin 170 mg/body, four courses) for hypopharyngeal
squamous cell carcinoma 3 years ago. After the chemother-
apy, a complete response was noted. The patient was a
smoker with a Brinkman index of 2400. Transbronchial
lung biopsy did not facilitate the diagnosis of malignancy.
After these examinations, we suspected the tumor to be
metastatic or primary lung carcinoma. Surgical biopsy and
treatment were selected. The tumor was diagnosed as pri-
mary lung carcinoma upon intraoperative diagnosis. Left
lower lobectomy and mediastinal lymph node dissection
were performed via video-assisted thoracic surgery. The
macroscopic specimen was solid and white with a smooth
margin (Figure 1D). The actual tumor was 35 × 25 ×
22 mm. Histological examination revealed that the tumor
was round with a clear margin (Figure 2A). The tumor
exhibited typical features of LCNEC such as palisadingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Imaging findings. (A) Plain chest radiograph revealed a mass in the left middle lung field. (B) Computed tomography (CT) revealed a
left lung tumor (28 × 22 mm) with smooth margin. (C) Positron-emission tomography revealed fluorodeoxyglucose accumulation in the mass.
(D) Macroscopic appearance of the resected tumor. The tumor was solid and white with a smooth margin.
Figure 2 Histological findings (hematoxylin and eosin). The tumor was round with a clear margin (A, original magnification). The tumor
exhibited typical features of large cell neuroendocrine carcinoma (LCNEC) such as palisading (B: ×100) and rosette-like structures (C: ×400). A few
very large, multinucleated, bizarre cells were observed (D: ×400).
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tumor cells were large with abundant and foamy cytoplasm.
In addition, a few very large, multinucleated, bizarre cells
were observed (Figure 2D). Immunohistochemical analysis
revealed diffuse and strong staining for vimentin, neural cell
adhesion molecule (NCAM), and neuron-specific enolase
(Figure 3). The tumor had a keratin profile of AE1/AE3 (+),
CK7 (+), and CK5/6 (+), and it was determined to be
primary lung cancer (data not shown). The tumor was
thus diagnosed as combined LCNEC with giant cell car-
cinoma, pl2, lymphatic permeation (−), blood vessel in-
vasion (+), and p-T2aN0M0 stage IB. The patient received
S-1 (TS-1, an oral fluoropyrimidine) chemotherapy. We
have performed close follow-up (every 2 months by CT);
no sign of recurrence has been noted for 8 months after
surgery.
Conclusions
According to the WHO classification, combined LCNEC
is categorized as LCNEC with components of adenocar-
cinoma, squamous cell carcinoma, giant cell carcinoma,
and/or spindle cell carcinoma [1]. In total, 10.6% of
LCNECs are classified as combined LCNEC, and compo-
nents of combined LCNEC are adenocarcinoma (33.3%),
squamous carcinoma (53.3%), and others (13.3%) [2].
Thus, combined LCNEC with giant cell carcinoma is rare.
Preoperative diagnosis of combined LCNEC is very
difficult. LCNEC usually appears as a well-defined and
lobulated tumor with no air bronchograms or calcifica-
tion [3], but this is not a specific sign. Therefore, the
diagnosis of combined LCNEC is primarily dependent
on pathological examination. In our case, CT revealed a
solid, round mass. Differential diagnosis also includesFigure 3 Immunohistochemical analysis. A: Vimentin, B: NCAM, C: Chromprimary lung carcinoma, metastatic carcinoma, or be-
nign tumor; thus, histopathological analysis is required
for a definitive diagnosis.
Immunohistochemical analysis is important for diag-
nosing LCNEC. Occasionally, LCNEC resembles the
other variants of LCC. The differential diagnosis is
dependent on the expression of neuroendocrine markers.
With regard to LCNEC, TTF-1, 34βE12 (cytokeratin
1.5.10.14), chromogranin A, synaptophysin, and NCAM,
are expressed in 40.9%, 2.2%, 68.5%, 84.2%, and 91.2% of
tumors, respectively [4].
There is no standard therapy for combined LCNEC.
Combination therapy for LCNEC may now be appropriate
in patients with combined LCNEC. Because LCNECs have
a poor prognosis, surgery alone is not sufficient. Sakaria
and colleagues [5] reported that the response rate of
LCNEC to platinum-based neoadjuvant chemotherapy
was 68%. In addition, univariate analysis revealed that
platinum + etoposide chemotherapy improved the overall
survival (OS) of patients with advanced-stage, completely
resected LCNEC [5]. In our case, we selected S-1 for adju-
vant chemotherapy because the patient previously re-
ceived cisplatin for hypopharyngeal squamous cell
carcinoma, and he did not want to receive aggressive
chemotherapy. Platinum-based chemotherapy should
be considered for patients who have not previously re-
ceived platinum-based chemotherapy.
Although LCNEC is categorized as a variant of LCC
[1], the biological behavior of LCNEC tumors resemble
that of small cell lung carcinoma (SCLC). Battafarano
and colleagues [6] demonstrated that, according to
histologic subtype, OS at 5 years was 30.2% for patients
with LCNECs and 30.3% for patients with combinedogranin A, D: Synaptophysin.
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LCNEC, and SCLC have equivalent prognoses. In pa-
tients with stage I LCNEC, the 5-year survival rate was
57.8%, compared with 31.9% for those with stage II
LCNEC [2]. Close observation is necessary.
In our case, staining for NCAM, which is located in
the cell membrane, was positive. However, staining for
synaptophysin and chromogranin A, which are secretory
granules was negative. The significance of neuroendo-
crine (NE) markers remains controversial. NE differenti-
ations may be involved in the prognosis of NE lung
cancer. Howe and colleagues [7] reported that the pres-
ence of immunohistochemically detected NE differenti-
ation in NSCLC was not of prognostic significance.
Conversely, among approximately 116 patients with
stage III/IV non-small cell lung carcinoma (NSCLC), the
chemotherapeutic response to paclitaxel and cisplatin
was significantly better in the NSCLC patients with NE
differentiation [8]. They showed that the percentage of
NE-positive tumor cells was an independent prognostic
factor associated with a favorable outcome. Another re-
port [9] revealed that the number of NE markers was
important for predicting the prognosis of LCC. OS was
better in LCCs with two or more NE markers [9]. There-
fore, we believe that NE markers are potential prognos-
tic factors for lung cancer.
In summary, because combined LCNEC with giant cell
carcinoma is an extremely rare tumor with high malig-
nant potential, multidisciplinary therapy and close
follow-up are advised. NE markers may have potential as
therapeutic and prognostic predictors.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Abbreviations
CEA: Carcinoembryonic antigen; CT: Computed tomography; LCC: Large cell
carcinoma; LCNEC: Large cell neuroendocrine carcinoma; NCAM: Neural cell
adhesion molecule; NE: Neuroendocrine; NSCLC: Non-small cell lung
carcinoma, overall survival; SCLC: Small cell lung carcinoma.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SH operated this case and analyzed all data. MK, KI, and YM provided
assistance for the operation. NM diagnosed the pathology of this case. All
authors read and approved the final manuscript.
Author details
1Respiratory Center, Asahikawa Medical University Hospital,
Midorigaoka-Higashi 2-1-1-1, Asahikawa, Hokkaido, Japan. 2Department of
Pathology, Asahikawa Medical University Hospital, Midorigaoka-Higashi
2-1-1-1, Asahikawa, Hokkaido, Japan.Received: 13 February 2013 Accepted: 7 August 2013
Published: 19 August 2013
References
1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: World Health
Organization Classification of Tumours. Tumours of the Lung, Pleura, Thymus
and Heart: Pathology and Genetics. Lyon: International Agency for Research
on Cancer Press; 2004.
2. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T,
Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K: Neuroendocrine
neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006,
24:70–76.
3. Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, Takei
H, Maeshima A, Murayama S, Moriyama N: CT findings of surgically
resected large cell neuroendocrine carcinoma of the lung in 38 patients.
Am J Roentgenol 2004, 182:87–91.
4. Sturm N, Lantuéjoul S, Laverrière MH, Papotti M, Brichon PY, Brambilla C,
Brambilla E: Thyroid transcription factor 1 and cytokeratins 1, 5, 10,
14 (34betaE12) expression in basaloid and large-cell neuroendocrine
carcinomas of the lung. Hum Pathol 2001, 32:918–925.
5. Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, Pietanza MC, Park BJ,
Travis WD, Rusch VW: Neoadjuvant and adjuvant chemotherapy in
resected pulmonary large cell neuroendocrine carcinomas: a single
institution experience. Ann Thorac Surg 2011, 92:1180–1187.
6. Battafarano RJ, Fernandez FG, Ritter J, Meyers BF, Guthrie TJ, Cooper JD,
Patterson GA: Large cell neuroendocrine carcinoma: an aggressive form
of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005, 130:166–172.
7. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS:
Neuroendocrine differentiation in non-small cell lung cancer and its
relation to prognosis and therapy. Histopathology 2005, 46:195–201.
8. Petrović M, Baskić D, Banković D, Ilić N: Neuroendocrine differentiation as
an indicator of chemosensitivity and prognosis in nonsmall cell lung
cancer. Biomarkers 2011, 16:311–320.
9. Harada M, Yokose T, Yoshida J, Nishiwaki Y, Nagai K: Immunohistochemical
neuroendocrine differentiation is an independent prognostic factor in
surgically resected large cell carcinoma of the lung. Lung Cancer 2002,
38:177–184.
doi:10.1186/1477-7819-11-205
Cite this article as: Hayashi et al.: Combined large cell neuroendocrine
carcinoma with giant cell carcinoma of the lungs: a case report. World
Journal of Surgical Oncology 2013 11:205.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
